Product Images Zevalin

This appears to be a table with percentages of subjects without an event in the ITT population, plotted against PFS (progression-free survival) time from randomization in months. The table shows data points at various time intervals ranging from 0 to 72 months with the corresponding percentage of subjects without events at each interval. The graph appears to show a decline in the percentage of subjects without events as the PFS time increases.*

Formulation Buffer for ZEVALIN® is a sterile and non-pyrogenic solution that can't be directly administered to people. It contains Albumin, Sodium Chloride, Sodium Phosphate Dibasic Dodecahydrate, Pentetic Acid, Potassium Phosphate Monobasic, and Potassium Chloride in specific amounts. This solution has been created for Acrotech Biopharma LLC.*

The text appears to be a description of a reaction vial for ZEVALIN® BEY. The vial is empty and is not intended for direct administration. It is described as sterile and non-pyrogenic. The other text appears to be illegible characters and symbols, making the meaning unclear.*

This appears to be a medical document outlining a treatment protocol that involves IV infusion of rituximab followed by Y-00 ZEVALIN for cancer patients. The infusion of rituximab occurs on both day 1 and either day 7 or 80r9. The document provides information on the recommended dosage of Y-00 ZEVALIN based on the patient's platelet count, with a caution against treating patients with a platelet count less than 100,000/mm?. Additionally, the maximum allowable dose of Y-90 ZEVALIN is 32.0 mCi (11.84) MBq.*